Efficacy of Hongjing I granule, an herbal medicine, in patients with mild to moderate erectile dysfunction in a randomized controlled trial

作者：R. Xu, Jun Guo, Chunhe Zhang, Qing Zhou, Q Gen, Fu Wang, Yu Zhao, Xin-Yun Luo, Yanfeng Li, Yi-Jia Fu, Xin Zhang, Wenzhi Wang, Jianxiong Ma, Jian Wang, Xiaojun Huang, Wenjie Huang, Bodong Lv · 发表于：Frontiers in Pharmacology · 年份：2024 · DOI：10.3389/fphar.2024.1367812 · 被引用次数：5 · 研究领域：Sexual function and dysfunction studies、Traditional Chinese Medicine Studies、Hormonal and reproductive studies

Background HJIG is a potential treatment for erectile dysfunction (ED) that has been used in China for over 20 years. We conducted a multi-center, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness and safety of the Chinese Herbal Medicine, Hongjing I granule (HJIG), in patients with mild to moderate erectile dysfunction (ED). Methods This study is structured as a randomized, double-blind, placebo-controlled trial, executed across multiple centers. The recruitment strategy is primarily oriented towards patients demonstrating a pronounced preference for solely leveraging traditional Chinese medicine (TCM) interventions, a preference that is widely observed within TCM healthcare settings. A total of 100 patients, presenting with mild to moderate ED, specifically linked to the traditional diagnostic criteria of qi deficiency and blood stasis, will be enrolled. These participants will be randomly distributed between the HJIG (N = 50) and placebo (N = 50) arms. The designated treatment period is set at 8 weeks. Primary outcome measures encompass the International Index of Erectile Function-Erectile Function domain (IIEF-EF) score, the Sexual Encounter Profile (SEP), and scores derived from the traditional Chinese medicine symptom evaluation. Results Of the 122 men enrolled, the baseline IIEF-EF score averaged 16.00 [IQR: 13.00, 18.00]. Eight weeks post-randomization, the HJIG group demonstrated a mean change in IIEF-EF scores of 7.80 (±3.25), compared...